Search - tctmd.com

Displaying 241 - 260 of 373

Sort: Relevancy | Date

News Conference News ESC 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

Shelley Wood

August 25, 2018

News Daily News

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

Michael O'Riordan

August 23, 2018

Podcast TCTMD Talking Points

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

August 22, 2018

News Daily News

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Michael O'Riordan

August 16, 2018

Podcast TCTMD Talking Points

REVASC: A Randomized Trial to Assess Recovery of Left Ventricular Function After PCI of Coronary Artery Chronic Total Occlusions

August 15, 2018

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

Podcast TCTMD Talking Points

DARE: A Randomized Trial of a Drug-Eluting Balloon vs a Metallic DES in Patients With Coronary Artery In-Stent Restenosis

June 20, 2018

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

News Daily News

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

Yael L. Maxwell

June 08, 2018

News Daily News

Liability Reform Changes How Docs Manage Suspected Coronary Artery Disease

Michael O'Riordan

June 07, 2018

News Conference News EuroPCR 2018

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

Michael O'Riordan

May 23, 2018

News Conference News EuroPCR 2018

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Michael O'Riordan

May 22, 2018

Podcast TCTMD Talking Points

ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease

May 02, 2018

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

News Daily News

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

Shelley Wood

April 18, 2018

News Daily News

Women With MI Less Likely Than Men to Fill Prescription for High-Intensity Statins

Michael O'Riordan

April 16, 2018

News Daily News

Time for Guidelines to Recommend ARBs Over ACE Inhibitors?

Shelley Wood

March 29, 2018

News Features

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Michael O'Riordan

March 23, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

Advertisement

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

REVASC: A Randomized Trial to Assess Recovery of Left Ventricular Function After PCI of Coronary Artery Chronic Total Occlusions

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

DARE: A Randomized Trial of a Drug-Eluting Balloon vs a Metallic DES in Patients With Coronary Artery In-Stent Restenosis

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

Liability Reform Changes How Docs Manage Suspected Coronary Artery Disease

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

Women With MI Less Likely Than Men to Fill Prescription for High-Intensity Statins

Time for Guidelines to Recommend ARBs Over ACE Inhibitors?

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content